Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,268 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].
Ohtake Y, Sudo K, Kojima Y, Seo T, Okuma H, Nishikawa T, Uno M, Uehara T, Ishikawa M, Tanioka M, Noguchi E, Shimomura A, Yonemori K, Kato T, Fujiwara Y, Tamura K. Ohtake Y, et al. Among authors: kojima y. Gan To Kagaku Ryoho. 2019 Oct;46(10):1525-1529. Gan To Kagaku Ryoho. 2019. PMID: 31631133 Japanese.
BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K. Kawachi A, et al. Among authors: kojima y. Breast Cancer Res Treat. 2020 Jun;181(2):323-329. doi: 10.1007/s10549-020-05647-w. Epub 2020 Apr 20. Breast Cancer Res Treat. 2020. PMID: 32314111 Clinical Trial.
HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix.
Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. Mizuno T, et al. Among authors: kojima y. Oncol Lett. 2020 Oct;20(4):38. doi: 10.3892/ol.2020.11899. Epub 2020 Jul 23. Oncol Lett. 2020. PMID: 32802162 Free PMC article.
Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer.
Mizuno T, Kojima Y, Yonemori K, Yoshida H, Sugiura Y, Ohtake Y, Okuma HS, Nishikawa T, Tanioka M, Sudo K, Shimomura A, Noguchi E, Kato T, Shimoi T, Uno M, Ishikawa M, Fujiwara Y, Ohe Y, Tamura K. Mizuno T, et al. Among authors: kojima y. Oncol Lett. 2020 Dec;20(6):336. doi: 10.3892/ol.2020.12200. Epub 2020 Oct 7. Oncol Lett. 2020. PMID: 33123247 Free PMC article.
Is adjuvant chemotherapy necessary in older patients with breast cancer?
Morita M, Shimomura A, Tokuda E, Horimoto Y, Kawamura Y, Ishizuka Y, Sekine K, Obayashi S, Kojima Y, Uemura Y, Higuchi T. Morita M, et al. Among authors: kojima y. Breast Cancer. 2022 May;29(3):498-506. doi: 10.1007/s12282-021-01329-7. Epub 2022 Jan 15. Breast Cancer. 2022. PMID: 35032302 Free PMC article.
Poor Treatment Outcomes with Second-Line Chemotherapy in Advanced Synovial Sarcoma.
Kojima Y, Shimoi T, Seo T, Yazaki S, Okuya T, Ohtake Y, Okuma HS, Shimomura A, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Tamura K, Yoshida A, Iwata S, Kobayashi E, Kawai A, Fujiwara Y, Yonemori K. Kojima Y, et al. Oncology. 2022;100(7):370-375. doi: 10.1159/000524500. Epub 2022 Apr 11. Oncology. 2022. PMID: 35405680
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.
Sanomachi T, Okuma HS, Kitadai R, Kawachi A, Yazaki S, Tokura M, Arakaki M, Saito A, Kita S, Yamamoto K, Maejima A, Kojima Y, Nishikawa T, Sudo K, Shimoi T, Noguchi E, Fujiwara Y, Sugino H, Shiino S, Suto A, Yoshida M, Yonemori K. Sanomachi T, et al. Among authors: kojima y. Front Oncol. 2023 Mar 27;13:1157789. doi: 10.3389/fonc.2023.1157789. eCollection 2023. Front Oncol. 2023. PMID: 37051545 Free PMC article.
Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma.
Uchihara M, Tanabe A, Kojima Y, Shimoi T, Maeshima AM, Umamoto K, Shimomura A, Shimizu C, Yamazaki Y, Nakamura E, Matsui Y, Takemura N, Miyazaki H, Sudo K, Yonemori K, Kajio H. Uchihara M, et al. Among authors: kojima y. Cancers (Basel). 2024 Jun 11;16(12):2191. doi: 10.3390/cancers16122191. Cancers (Basel). 2024. PMID: 38927897 Free PMC article.
Neutrophil-to-lymphocyte ratio as a prognostic factor for patients with metastatic or recurrent breast cancer treated using capecitabine: a retrospective study.
Takamizawa S, Shimoi T, Satomi-Tsushita N, Yazaki S, Okuya T, Kojima Y, Sumiyoshi-Okuma H, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Yonemori K. Takamizawa S, et al. Among authors: kojima y. BMC Cancer. 2022 Jan 14;22(1):64. doi: 10.1186/s12885-021-09112-9. BMC Cancer. 2022. PMID: 35027011 Free PMC article.
2,268 results